Aldeyra Therapeutics, Inc (ALDX)

Etorro trading 970x250
Aldeyra Therapeutics, Inc (ALDX) Logo

About Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company’s portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts. Address: 131 Hartwell Avenue, Lexington, MA, United States, 02421

Aldeyra Therapeutics, Inc News and around…

Latest news about Aldeyra Therapeutics, Inc (ALDX) common stock and company :

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
21 Oct, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent business highlights.

Notable Tuesday Option Activity: BLMN, CVX, ALDX
05 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bloomin' Brands Inc (BLMN), where a total volume of 6,224 contracts has been traded thus far today, a contract volume which is representative of approximately 622,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.4% of BLMN's average daily trading volume over the past month, of 1.4 million shares..

January 2022 Options Now Available For Aldeyra Therapeutics (ALDX)
28 Sep, 2021 FinancialContent

Investors in Aldeyra Therapeutics Inc (ALDX) saw new options begin trading today, for the January 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 115 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
09 Sep, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET.

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
02 Sep, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

How The Parts Add Up: VTWG Headed For $268
01 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $267.60 per unit.

Noteworthy Tuesday Option Activity: ALDX, CPLG, CAL
31 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aldeyra Therapeutics Inc (ALDX), where a total volume of 5,320 contracts has been traded thus far today, a contract volume which is representative of approximately 532,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 103.1% of ALDX's average daily trading volume over the past month, of 516,140 shares..

Notable Thursday Option Activity: CC, ALDX, FB
12 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Chemours Co (CC), where a total volume of 12,374 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 125.1% of CC's average daily trading volume over the past month, of 988,805 shares..

Aldeyra Therapeutics (ALDX) Q2 2021 Earnings Call Transcript
07 Aug, 2021 FinancialContent

ALDX earnings call for the period ending June 30, 2021.

What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?
07 Aug, 2021 Yahoo! Finance

If you want to know who really controls Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ), then you'll have to look at the...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
05 Aug, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.

Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
04 Aug, 2021 FinancialContent

TheFDA has granted orphan drug designationtoAldeyra Therapeutics Inc's(NASDAQ: ALDX) ADX-2191 to treat ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
04 Aug, 2021 FinancialContent

Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The ...

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
04 Aug, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). There are no approved drug treatments for patients with RP, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. The disease affects an estimated 82,000-110,000 individuals in the United States, and approximately 1 in 4,000 people worldwide.

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Is Aldeyra Therapeutics Inc (ALDX) A Good Stock To Buy?
29 Jul, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
29 Jul, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights.

XBI's Holdings Could Mean 74% Gain Potential
28 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.34 per unit.

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
21 Jul, 2021 Yahoo! Finance

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
20 Jul, 2021 FinancialContent

TheFDA has granted Orphan Drug DesignationtoAldeyra Therapeutics Inc's(NASDAQ: ALDX) ADX-2191 ...

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
20 Jul, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitreoretinal lymphoma (PVRL). There are no approved treatments for PVRL, a rare, aggressive, high-grade cancer that affects approximately 2,800 people in the United States, with approximately 600 new cases diagnosed annually.

12 Health Care Stocks Moving In Monday's Pre-Market Session
19 Jul, 2021 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. ...

Interesting ALDX Put And Call Options For March 2022
16 Jul, 2021 FinancialContent

Investors in Aldeyra Therapeutics Inc (ALDX) saw new options become available this week, for the March 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

First Week of August 20th Options Trading For Aldeyra Therapeutics (ALDX)
09 Jul, 2021 FinancialContent

Investors in Aldeyra Therapeutics Inc (ALDX) saw new options become available this week, for the August 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALDX options chain for the new August 20th contracts and identified one put and one call contract of particular interest.

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
01 Jul, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective after the U.S. market opened on June 28, 2021, as part of the 2021 Russell reconstitution.

Aldeyra Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating
29 Jun, 2021 FinancialContent

Aldeyra Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Analysts Expect XBI Will Reach $216
24 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $215.74 per unit.

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
27 May, 2021 FinancialContent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 4:30 p.m. ET.

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More
08 May, 2021 FinancialContent

Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive officers were among those buying shares this past week.

Aldeyra Therapeutics, Inc (ALDX) is a NASDAQ Common Stock listed in , ,

970x250